The World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the **LC16m8 mpox vaccine**, marking it as the **second approved vaccine** for mpox following the Director-General’s declaration of an mpox public health emergency in August 2024. 

This decision aims to enhance access to vaccines in countries facing rising mpox cases, including **80 countries** globally, with the Democratic Republic of the Congo (DRC) being the hardest-hit, reporting over **39,000 suspected cases and 1,000 deaths**. 

Japan will donate **3.05 million** doses of the vaccine to DRC. LC16m8 is recommended for individuals over **one year** of age and is administered using a bifurcated needle. 

WHO’s approval comes after assessments of safety and efficacy, especially in high-risk groups, though it is not recommended for use in pregnant individuals or the immunocompromised. This move strengthens global efforts to control the ongoing mpox outbreak.
                                                                                                                                                                                                         Source: WHO [Read full story](https://www.who.int/news/item/19-11-2024-who-adds-lc16m8-mpox-vaccine-to-emergency-use-listing)